Melatonin-triggered post-transcriptional and post-translational modifications of ADAMTS1 coordinately retard tumorigenesis and metastasis of renal cell carcinoma
- 1 September 2020
- journal article
- research article
- Published by Wiley in Journal of Pineal Research
- Vol. 69 (2), e12668
- https://doi.org/10.1111/jpi.12668
Abstract
A disintegrin and metalloprotease with thrombospondin motifs (ADAMTS) family are widely implicated in tissue remodeling events manifested in cancer development. ADAMTS1, the most fully characterized ADAMTS, plays conflicting roles in different cancer types; however, the role of ADAMTS1 in renal cell carcinoma (RCC) remains unclear. Herein, we found that ADAMTS1 is highly expressed in RCC tissues compared to normal renal tissues, and its expression was correlated with an advanced stage and a poor prognosis of RCC patients. In vitro, we observed higher expression of ADAMTS1 in metastatic (m)RCC cells compared to primary cells, and manipulation of ADAMTS1 expression affected cell invasion and clonogenicity. Results from protease array showed that ADAMTS1 is modulated by melatonin through mechanisms independent of the MT1 receptor in mRCC cells, and overexpression of ADAMTS1 relieved the invasion/clonogenicity and growth/metastasis inhibition imposed by melatonin treatment in vitro and in an orthotopic xenograft model. The human microRNA (miR) OneArray showed that miR-181d and miR-let-7f were induced by melatonin and, respectively, targeted the 3'-UTR and non-3'-UTR of ADAMTS1 to suppress its expression and mRCC invasive ability. Clinically, RCC patients with high levels of miR-181d or miR-let-7f and a low level of ADAMTS1 had the most favorable prognoses. In addition, ubiquitin/proteasome-mediated degradation of ADAMTS1 can also be triggered by melatonin. Together, our study indicates that ADAMTS1 may be a useful biomarker for predicting RCC progression. The novel convergence between melatonin and ADAMTS1 post-transcriptional and post-translational regulation provides new insights into the role of melatonin-induced molecular regulation in suppressing RCC progression.Funding Information
- Taipei Medical University (109‐wf‐swf‐05, TMU105‐AE1‐B23)
- Ministry of Science and Technology, Taiwan (106‐2314‐B‐038‐092)
This publication has 56 references indexed in Scilit:
- Inhibition of MMP-9 using a pyrrole-imidazole polyamide reduces cell invasion in renal cell carcinomaInternational Journal of Oncology, 2013
- Analysis of CDS-located miRNA target sites suggests that they can effectively inhibit translationGenome Research, 2013
- Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinomaWorld Journal of Surgical Oncology, 2013
- ADAMTS1 Contributes to the Acquisition of an Endothelial-like Phenotype in Plastic Tumor CellsCancer Research, 2010
- ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasisGenes & Development, 2009
- Argonaute HITS-CLIP decodes microRNA–mRNA interaction mapsNature, 2009
- Plasma matrix metalloproteinase‐7 as a metastatic marker and survival predictor in patients with renal cell carcinomasCancer Science, 2008
- Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectivelyOncogene, 2005
- Renal-Cell CarcinomaThe New England Journal of Medicine, 2005
- Role of ADAMTS-1 in AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2005